| Drug General Information |
| Drug ID |
D09BXJ
|
| Former ID |
DIB006977
|
| Drug Name |
PF-5177624
|
| Synonyms |
PF-05177624; PF-05197281; 3-phosphoinositide-dependent kinase-1 inhibitor (cancer), Pfizer
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Investigative |
[1]
|
|---|
| Company |
Pfizer Inc
|
| Target and Pathway |
| Target(s) |
3-phosphoinositide dependent protein kinase-1 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Insulin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Aldosterone-regulated sodium reabsorption
|
|
Toxoplasmosis
|
|
Hepatitis C
|
|
Proteoglycans in cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Non-small cell lung cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
p53 pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
BCR signaling pathway
|
|
Insulin Pathway
|
|
TCR signaling in naï
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
TCR signaling in naï
|
|
FAS (CD95) signaling pathway
|
|
mTOR signaling pathway
|
|
CXCR4-mediated signaling events
|
|
IGF1 pathway
|
|
Class I PI3K signaling events
|
|
ErbB1 downstream signaling
|
|
IL8- and CXCR2-mediated signaling events
|
|
CXCR3-mediated signaling events
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Class I PI3K signaling events mediated by Akt
|
|
IL8- and CXCR1-mediated signaling events
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
FGF signaling pathway
|
|
TGF-beta receptor signaling
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Insulin Signalling
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
Activation of AKT2
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated NF-kB activation
|
|
Integrin alphaIIb beta3 signaling
|
|
CD28 dependent PI3K/Akt signaling
|
|
CTLA4 inhibitory signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
VEGFR2 mediated vascular permeability
|
|
VEGFR2 mediated cell proliferation
|
|
CLEC7A (Dectin-1) signaling
|
|
RHO GTPases activate PKNs
|
|
Constitutive Signaling by AKT1 E17K in Cancer
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
TCR Signaling Pathway
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Focal Adhesion
|
|
Cardiac Hypertrophic Response
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
BDNF signaling pathway
|
|
Interleukin-11 Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
TCR signaling
|
|
Signaling by Insulin receptor
|
|
Integrin-mediated Cell Adhesion
|
|
GPVI-mediated activation cascade
|
|
GPCR downstream signaling
|
|
Costimulation by the CD28 family
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402. |
|---|
